中危甲状腺乳头状癌初始治疗显效后的早期复发风险因素
本研究回顾性纳入217例美国甲状腺协会中危甲状腺乳头状癌且初始治疗(全甲状腺切除+100-150 mCi放射性碘)后疗效满意者,中位随访42个月,复发率7.4%。多因素分析显示pN1b受累、侧颈放射性碘摄取及消融前甲状腺球蛋白>10 ng/mL与早期复发显著相关。
要点
- 中危甲状腺乳头状癌初始治疗显效后早期复发率仍达7.4%。
- pN1b受累和侧颈放射性碘摄取是早期复发的独立危险因素。
- 消融前甲状腺球蛋白>10 ng/mL与早期复发风险增加相关。
核心结论
- 中危甲状腺乳头状癌初始治疗显效后早期复发率7.4%,高于预期。
- 早期复发与侧颈淋巴结转移、侧颈放射性碘摄取及消融前甲状腺球蛋白>10 ng/mL显著相关。
研究设计与样本
- 回顾性队列研究,纳入217例美国甲状腺协会中危甲状腺乳头状癌患者,均接受全甲状腺切除及100-150 mCi放射性碘治疗并记录为疗效满意。
主要发现
- 中位随访42个月(范围17-88个月),16例(7.4%)出现复发,其中结构复发10例(62.5%),生化复发6例。
- logistic回归显示早期复发与pN1b受累(OR=10.81,95%CI 1.87-62.59)、侧颈放射性碘摄取(OR=6.06,95%CI 1.67-22)及消融前甲状腺球蛋白>10 ng/mL(OR=4.01,95%CI 1.16-13.85)相关。
- Cox回归显示pN1b受累(HR=9.6,95%CI 1.91-48.52)和侧颈放射性碘摄取(HR=5.95,95%CI 1.86-18.97)与复发显著相关。
临床怎么用
- 对中危甲状腺乳头状癌初始治疗显效者,应关注pN1b受累、侧颈放射性碘摄取及消融前甲状腺球蛋白>10 ng/mL以评估早期复发风险。
局限性
- 回顾性设计,样本量有限,随访时间范围较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with excellent response to initial therapy have a low rate of tumor recurrence. The objectives of this study were to evaluate the rate of early tumor recurrence in patients with intermediate-risk papillary thyroid cancer who had an excellent response to initial treatment and to identify risk factors. METHODS: This retrospective cohort study included 217 patients with American Thyroid Association intermediate-risk papillary thyroid cancer who had a documented excellent response to initial treatment (total thyroidectomy and adjuvant therapy with 100-150 mCi [3.7-5.5 GBq] of radioactive iodine [RAI]). The assessed outcome was recurrence, defined as new evidence of disease after any disease-free period. Multivariate logistic regression and Cox regression models were used to determine the factors associated with recurrence upon recording clinical, surgical, and pathology variables. RESULTS: Sixteen (7.4%) cases of recurrent disease were documented after a median follow-up period of 42 months (range 17-88 months). Structural recurrence was documented in 10 (62.5%) patients, and biochemical recurrence was documented in the remaining six patients. The logistic regression model identified a significant association between early recurrence and pN1b involvement (odds ratio [OR] = 10.81 [confidence interval (CI) 1.87-62.59]), lateral neck RAI uptake (OR = 6.06 [CI 1.67-22]), and pre-ablation thyroglobulin >10 ng/mL (OR = 4.01 [CI 1.16-13.85]). Variables that proved significant in the Cox regression model were: pN1b involvement (hazard ratio = 9.6 [CI 1.91-48.52]) and lateral neck RAI uptake (hazard ratio = 5.95 [CI 1.86-18.97]). CONCLUSION: The observed early recurrence rate of 7.4% is uncharacteristically high for a population of patients who had an excellent response to initial treatment. The significant association that was found between recurrent disease and lateral neck lymph node metastasis, lateral neck I131 uptake in post-therapy whole-body scan, and pre-ablation thyroglobulin levels >10 ng/mL indicates that early recurrence (<5 years) most likely indicates progression of micrometastatic disease already present at diagnosis and unsuccessfully eradicated with initial therapy.
引用
- Llamas-Olier AE, Cuéllar DI, Buitrago G, et al. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy. Thyroid. 2018. PMID: 30105948. doi:10.1089/thy.2017.0578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。